Document Detail


Temporal analysis of intratumoral metabolic heterogeneity characterized by textural features in cervical cancer.
MedLine Citation:
PMID:  23340594     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The aim of this pilot study was to explore heterogeneity in the temporal behavior of intratumoral [(18)F]fluorodeoxyglucose (FDG) accumulation at a regional scale in patients with cervical cancer undergoing chemoradiotherapy.
METHODS: Included in the study were 20 patients with FIGO stages IB1 to IVA cervical cancer treated with combined chemoradiotherapy. Patients underwent FDG PET/CT before treatment, during weeks 2 and 4 of treatment, and 12 weeks after completion of therapy. Patients were classified based on response to therapy as showing a complete metabolic response (CMR), a partial metabolic response (PMR), or residual disease and the development of new disease (NEW). Based on the presence of residual primary tumor following therapy, patients were divided into two groups, CMR and PMR/NEW. Temporal profiles of intratumoral FDG heterogeneity as characterized by textural features at a regional scale were assessed and compared with those of the standardized uptake value (SUV) indices (SUVmax and SUVmean) within the context of differentiating response groups.
RESULTS: Textural features at a regional scale with emphasis on characterizing contiguous regions of high uptake in tumors decreased significantly with time (P < 0.001) in the CMR group, while features describing contiguous regions of low uptake along with those measuring the nonuniformity of contiguous isointense regions in tumors exhibited significant temporal changes in the PMR/NEW group (P < 0.03) but showed no persistent trends with time. Both SUV indices showed significant changes during the course of the disease in both patient groups (P < 0.001 for SUVmax and SUVmean in the CMR group; P = 0.0109 and 0.0136, respectively, for SUVmax and SUVmean in the PMR/NEW group), and also decreased at a constant rate in the CMR group and decreased up to the 4th week of treatment and then increased in the PMR/NEW group.
CONCLUSION: The temporal changes in the heterogeneity of intratumoral FDG distribution characterized at a regional scale using image-based textural features may provide an adjunctive or alternative option for understanding tumor response to chemoradiotherapy and interpreting FDG accumulation dynamics in patients with malignant cervical tumors during the course of the disease.
Authors:
Fei Yang; Maria A Thomas; Farrokh Dehdashti; Perry W Grigsby
Related Documents :
978214 - Granulomatous angitis of the central nervous system. case report and review.
3355984 - Central nervous system involvement in malignant melanoma.
17628684 - Incidence of new tumor formation in patients with hereditary retinoblastoma treated wit...
17675264 - Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute m...
24164784 - Comparative study of percutaneous radiofrequency ablation and hepatic resection for sma...
6275974 - Mediastinal lymph-node biopsy is a definitive staging procedure for bronchogenic carcin...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2013-01-23
Journal Detail:
Title:  European journal of nuclear medicine and molecular imaging     Volume:  40     ISSN:  1619-7089     ISO Abbreviation:  Eur. J. Nucl. Med. Mol. Imaging     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-11     Completed Date:  2013-09-25     Revised Date:  2014-05-07    
Medline Journal Info:
Nlm Unique ID:  101140988     Medline TA:  Eur J Nucl Med Mol Imaging     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  716-27     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Chemoradiotherapy
Female
Fluorodeoxyglucose F18 / diagnostic use
Humans
Middle Aged
Neoplasm Staging
Positron-Emission Tomography
Time Factors
Treatment Outcome
Uterine Cervical Neoplasms / metabolism*,  pathology*,  radionuclide imaging,  therapy
Grant Support
ID/Acronym/Agency:
R01 CA136931/CA/NCI NIH HHS; R01 CA136931/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0Z5B2CJX4D/Fluorodeoxyglucose F18
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  (124)I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with pos...
Next Document:  Clinical value of (11)C-methionine PET/CT in patients with plasma cell malignancy: comparison with (...